TNTL for diabetic eye disease (non-proliferative)
Part of Eyes & vision clinical trials.
This study tests if a drug called TNTL can help people with type 2 diabetes who have early-stage diabetic eye disease (non-proliferative diabetic retinopathy) without severe vision loss. It aims to see if the treatment is safe and effective in slowing or improving the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have type 2 diabetes and have been told you have mild or moderate non-proliferative diabetic retinopathy (NPDR - an early stage of diabetic eye disease).
- Your vision in the eye being studied is still good (at least 20/200 on a vision chart).
- You have not had any severe eye diseases like macular edema, glaucoma, or retinal detachment.
- Your blood sugar control is fair (HbA1c level of 8.5% or lower in the last few months).
- You agree to follow the study procedures, including taking the study drug and attending visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an eye implant (OTX-TKI) that slowly releases a medicine to slow or stop worsening of non-proliferative diabetic retinopathy (NPDR) — an early form of diabetic eye disease. It's for people with moderately severe to severe NPDR who haven't had significant treatments like laser or injections in that eye.
This study tests if a simple, non-invasive treatment called remote ischemic conditioning (briefly restricting blood flow to one arm using a special cuff) can help slow down early-stage diabetic eye disease in people with type 2 diabetes. You join the study to potentially prevent your retinopathy from getting worse.
This study tests whether using a special eye scan (OCTA) to guide targeted laser treatment can slow down the progression of areas with poor blood flow in the retina of people with diabetic retinopathy. The goal is to prevent the condition from getting worse and help preserve your vision.
This study closely follows people with type 2 diabetes who have early signs of diabetic retinopathy (damage to the retina from diabetes) to see how the condition changes over time. It does not test a new treatment but monitors the eye's health closely. It may be a good fit if you have diabetic retinopathy that does not need immediate treatment.
This study tests a ginkgo biloba extract (EGb761) to see if it can help prevent or slow early diabetic retinopathy. Participants will receive the extract or a placebo (inactive pill), and their eye health will be monitored over time.
This study tests whether an experimental eye drop can slow or treat early-stage diabetic retinopathy. If you have diabetes-related vision changes, this treatment might help prevent the condition from getting worse.
Hear when a new Non-Proliferative Diabetic Retinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.